Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU

Executive Summary

Samsung Bioepis is poised to grab the leading position in the trastuzumab biosimilar market in Europe as its biosimilar Ontruzant gets the European Commission's approval ahead of the competition.

You may also be interested in...



Celltrion's Trastuzumab Biosimilar Gets EC Nod

With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.

Celltrion's Trastuzumab Biosimilar Gets EC Nod

With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.

Roche: No Major M&A Needed To Offset Biosimilar Threat

Rather than buying its way out of trouble, Roche is backing its new products, notably the multiple sclerosis drug Ocrevus, the PD-L1 inhibitor Tecentriq and the lung cancer treatment Alecensa to offset the battering from biosimilar competition to some of its big-selling cancer therapies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel